866-997-4948(US-Canada Toll Free)

Eldepryl Analysis and Estimates from 2002 to 2012

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 32 Pages


GlobalDatas pharmaceuticals report, Eldepryl Analysis and Estimates from 2002 to 2012 provides Eldepryl sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2012). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Eldepryl including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Eldepryl including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2012 for Eldepryl in the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Parkinsons Disease 4
2.2 Symptoms of Parkinsons Disease 4
2.3 Diagnosis of Parkinsons disease 5
2.4 Parkinsons Disease Treatment Strategies 5
2.5 Parkinsons Disease Market 6
2.6 Epidemiology 6
2.7 Parkinsons Disease by Age and Gender 6
2.8 Etiology 7
2.9 GlobalData Report Guidance 7

3 Parkinsons Disease: Market Characterization 8
3.1 Parkinsons Disease Market 8
3.2 Parkinsons Disease Market Forecasts and CAGR 8
3.3 Factors Affecting Parkinsons Disease Market 9
3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder 9
3.3.2 Increase in Old Age Population 9
3.3.3 Patent Expiry of Prominent Drugs 9

4 Stages of Parkinsons Disease and Comparison of Treatments 10
4.1 The Hoehn and Yahr Scale 10
4.2 Modified Hoehn and Yahr Scale 10
4.3 The UPDRS 11

5 Staging of Parkinsons Disease 14
5.1 Distribution of Parkinsons disease Patients by Age Groups 14
5.2 Distribution of Patients by Stages 14

6 Eldepryl 15
6.1 Introduction 15
6.2 Mechanism of Action 15
6.3 Clinical Studies 15
6.3.1 Tolerability and Efficacy after the PatientsSwitch From Oral Selegiline (Eldepryl) to Orally Disintegrating Selegiline (Zelapar) in Patients with Parkinsons Disease 15
6.4 Approval History of Eldepryl 15
6.5 Factors Affecting Sales of Eldepryl 16
6.5.1 Less patient pool 16
6.5.2 Patent Expiry 16
6.5.3 Zelapars Approval 16
6.5.4 Intense Competition 16
6.6 Intensity of Competition 16
6.7 Sales Estimates 17
6.7.1 Target Patient Pool of Eldepryl 17
6.7.2 Market Penetration 18
6.7.3 Dosing 18
6.7.4 Annual Cost of Therapy 18
6.7.5 Sales Estimates of Eldepryl 19

7 Parkinson Disease Market: Appendix 28
7.1 Market Definitions 28
7.2 List of Abberiviations 28
7.3 Research Methodology 28
7.3.1 Coverage 28
7.3.2 Secondary Research 29
7.3.3 Forecasting 29
7.3.4 Number of Patients Approved to take the Drug 29
7.3.5 Net Penetration of Drug 29
7.3.6 Net Annual Dosing 30
7.3.7 Annual Cost of Therapy 30
7.3.8 Primary Research 30
7.3.9 Expert Panels 31
7.4 Drug Sales Estimates Model 31
7.5 Contact Us 31
7.6 Disclaimer 31
7.7 Sources 32

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 4
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 4: Four Items, Part 1 of UPDRS 11
Table 5: Thirteen Items, Part 2 of Parkinsons disease 11
Table 6: Fourteen Items, Part 3 of UPDRS 12
Table 7: Fourteen Items, Part 3 of UPDRS 12
Table 8: Distribution of Parkinsons patients according to Hoehn and Yahr Classification 14
Table 9:Approval History 15
Table 10:Efficacy Comparison of Eldepryl 17
Table 11: Annual Cost of Eldepryl for Parkinsons Disease, 2011 18
Table 12: Eldepryl, Parkinsons Disease, Global, Sales Estimates ($m), 20022012 19
Table 13: Eldepryl, Parkinsons Disease, The US, Sales Estimates ($m), 20022012 20
Table 14: Eldepryl, Parkinsons Disease, The UK, Sales Estimates ($m), 20022012 21
Table 15: Eldepryl, Parkinsons Disease, France, Sales Estimates ($m), 20022012 22
Table 16: Eldepryl, Parkinsons Disease, Germany, Sales Estimates ($m), 20022012 23
Table 17: Eldepryl, Parkinsons Disease, Italy, Sales Estimates ($m), 20022012 24
Table 18: Eldepryl, Parkinsons Disease, Spain, Sales Estimates ($m), 20022012 25
Table 19: Eldepryl, Parkinsons Disease, Japan, Sales Estimates ($m), 20022012 26

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons disease and Their Potential Sites of Action in the CNS 5
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 6
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 8
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 9
Figure 5: Points Distribution of UPDRS 13
Figure 6: Distribution of Parkinsons patients by Hoehn & Yahr Classification 14
Figure 7: Drug Model Diagram of Eldepryl in the US, EU and Japan 17
Figure 8: Eldepryl, Parkinsons Disease, Global, Sales Estimates ($m), 20022012 19
Figure 9: Eldepryl, Parkinsons Disease, The US, Sales Estimates ($m), 20022012 20
Figure 10: Eldepryl, Parkinsons Disease, The UK, Sales Estimates ($m), 20022012 21
Figure 11: Eldepryl, Parkinsons Disease, France, Sales Estimates ($m), 20022012 22
Figure 12: Eldepryl, Parkinsons Disease, Germany, Sales Estimates ($m), 20022012 23
Figure 13: Eldepryl, Parkinsons Disease, Italy, Sales Estimates ($m), 20022012 24
Figure 14: Eldepryl, Parkinsons Disease, Spain, Sales Estimates ($m), 20022012 25
Figure 15: Eldepryl, Parkinsons Disease, Japan, Sales Estimates ($m), 20022012 26
Figure 16: Eldepryl, Parkinsons Disease, Sales Distribution by Country (%), 2006 27
Figure 17: Drug Model Diagram 30
Figure 18: Patients Approved for the Drug 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *